Loading...
XSTOCMOTEC B
Market cap3mUSD
Dec 23, Last price  
1.47SEK
1D
2.80%
1Q
-34.96%
Jan 2017
-97.23%
IPO
-97.01%
Name

Scandinavian ChemoTech AB

Chart & Performance

D1W1MN
XSTO:CMOTEC B chart
P/E
—
P/S
12.98
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
41.64%
Rev. gr., 5y
38.19%
Revenues
3m
+496.62%
0013,8942,084,36327,243560,000556,000131,00049,000473,0002,822,000
Net income
-21m
L-14.19%
-7,459-28,137-1,180,834-8,139,023-8,331,608-4,797,000-12,585,000-12,499,000-18,418,000-24,580,000-21,091,000
CFO
-18m
L-7.15%
0-40,907-474,990-7,516,783-14,973,961-4,579,000-11,226,000-8,494,000-19,183,000-19,630,000-18,226,000

Profile

Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.
URL
https://www.chemotech.se/
IPO date
Dec 06, 2016
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑062016‑062015‑06
Income
Revenues
2,822
496.62%
473
865.31%
49
-62.60%
Cost of revenue
3,735
3,435
(2,810)
Unusual Expense (Income)
NOPBT
(913)
(2,962)
2,859
NOPBT Margin
5,834.69%
Operating Taxes
1,834
675
Tax Rate
23.61%
NOPAT
(913)
(4,796)
2,184
Net income
(21,091)
-14.19%
(24,580)
33.46%
(18,418)
47.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
18,379
12,556
32,368
BB yield
-36.60%
-24.94%
-21.95%
Debt
Debt current
53
Long-term debt
Deferred revenue
Other long-term liabilities
1,820
Net debt
(923)
(6,274)
(8,779)
Cash flow
Cash from operating activities
(18,226)
(19,630)
(19,183)
CAPEX
(680)
(331)
(3,180)
Cash from investing activities
(468)
(603)
(3,330)
Cash from financing activities
13,765
17,257
29,710
FCF
(3,063)
(254)
(2,595)
Balance
Cash
923
5,852
8,682
Long term investments
422
150
Excess cash
782
6,250
8,830
Stockholders' equity
(100,020)
(87,649)
(12,928)
Invested Capital
111,051
101,641
36,898
ROIC
7.60%
ROCE
11.93%
EV
Common stock shares outstanding
18,600
9,969
8,656
Price
2.70
-46.53%
5.05
-70.36%
17.04
25.76%
Market cap
50,221
-0.24%
50,342
-65.87%
147,495
121.07%
EV
49,298
60,807
203,884
EBITDA
1,767
(14)
5,675
EV/EBITDA
27.90
35.93
Interest
1,403
1,897
675
Interest/NOPBT
23.61%